Expert Interviews

Learn why hidradenitis suppurativa is often mistaken for infection and who it affects—key myths that delay diagnosis and proper care.

Learn why hidradenitis suppurativa isn’t an infection, isn’t caused by poor hygiene, and can affect anyone—key myths delaying diagnosis.

This episode features panelists moving beyond HiSCR50 to examine the “depth of response” endpoints—HiSCR75, HiSCR90, and HiSCR100—and what they mean clinically.

Discover how rifamylast foam, a new FDA-approved PDE4 inhibitor, offers steroid-free relief for seborrheic dermatitis—calms itch, face-safe.

Discover how FDA-approved rifamylast foam targets PDE4 to calm seborrheic dermatitis—face-safe, steroid-free relief for itch and redness.

Explore effective strategies for managing poorly controlled psoriasis, focusing on systemic treatments and patient-centered care for optimal outcomes.

Explore the importance of multidisciplinary care in rheumatology, emphasizing collaboration among specialists for optimal patient outcomes.

Mark Lebwohl, MD, reviews how the AdvanceAD-Tx 487-GEP test identifies which patients are likely to need a JAK inhibitor rather than a biologic.

Dr. Madigan presents the case of a 50-year-old woman with refractory indolent systemic mastocytosis whose severe gastrointestinal and cutaneous symptoms persisted despite a high medication burden of antihistamines, cromolyn sodium, and oral steroids.

On National Skin Barrier Day, dermatologists share barrier-saving tips for gentle cleansing, daily sunscreen, smarter product audits, and retinoid adherence.

Compared with topical regimens, Rossi notes PDT provides a shorter recovery window and fewer adherence challenges.

This episode examines the persistent barriers that contribute to the delayed diagnosis of hidradenitis suppurativa, highlighting the need for greater disease awareness, proactive screening by frontline providers, and the growing role of patient self-advocacy in improving earlier detection.

This episode explores the multidimensional burden of hidradenitis suppurativa, highlighting its physical, emotional, and economic impacts on patients while emphasizing the importance of compassionate care and improved disease recognition.

In this episode, our experts delve into the primary efficacy results of the STOP HS trials, focusing on HiSCR50 at weeks 12 and 24 and how to interpret those numbers.

In this episode, the panelists explore the baseline characteristics of the STOP HS trials and why they matter for interpreting the results and applying them to practice. They first emphasize the achievement of running a >1,200‑patient, global phase 3 HS program, urging clinicians everywhere to refer patients to clinical trials to keep building robust data.

Mark Lebwohl, MD, discusses how the 487-GEP test may help clinicians identify the most appropriate systemic therapy for patients with AD earlier in the treatment journey.

Red light–activated photodynamic therapy offers an effective field-based option for treating both visible and subclinical actinic keratoses.

Dylan Timmermann, PA-C, reflects on the experiences that shaped his career trajectory in dermatology and offers insights relevant to physician assistants and nurse practitioners entering the specialty.

Rethink seborrheic dermatitis care: limit facial steroids, use antifungals wisely, and watch emerging barrier-safe targeted therapies.

Early seborrheic dermatitis treatment reduces inflammation, prevents worsening, and boosts quality of life; experts explain pediatric vs adult goals and mask-triggered flares.

Experts discuss strategies for managing patient remission in psoriatic arthritis, emphasizing personalized treatment plans and ongoing patient engagement.

Explore the impact of patient-centered approaches in dermatology, emphasizing long-term success and quality of life in psoriasis treatment.

Dr. Madigan explains that for a patient with newly diagnosed indolent systemic mastocytosis (ISM), initial management focuses on best supportive therapies like cetirizine and cromolyn sodium while emphasizing that an epinephrine auto-injector is a mandatory component of care due to high anaphylaxis risks.

Ruiz Dasilva emphasized case-based strategies for managing complex inflammatory dermatoses, highlighted chronic pruritus as an urgent unmet need, and called for more standardized designs for atopic dermatitis trials.

James Del Rosso, DO, shares rapid-fire insights on mentorship, HS advances, contact dermatitis triggers, and teen skin care marketing concerns.

This episode, titled Seborrheic Dermatitis Across Skin Tones and Long-Term Disease Burden, features dermatology experts discussing the following critical questions: How might presentation of SD differ in various skin tones? What challenges do you encounter when diagnosing SD in patients with skin color? In your experience, what long-term complications arise when SD is inadequately treated or remains uncontrolled over time?

Seborrheic dermatitis varies by age, affects scalp and face, drives itching and stigma, and lowers quality of life—highlighting newer targeted treatments.

Recent data reveals insights on psoriasis treatment, highlighting the importance of achieving full clearance for long-term control and patient outcomes.

Healthcare professionals discuss evaluating disease control and treatment response using objective findings and patient assessments in dermatology.

At Winter Clinical Miami, Lisa Swanson, MD, FAAD, shared practical, prior authorization–free treatment strategies while calling for expanded therapeutic options and earlier research inclusion for children under 12.